Annual And Sustainability Report

Overview

The report presents Sobi's 2024 performance as a global rare-disease biopharma group, with total revenue of SEK 26,027 M and 1,896 employees. Sustainability disclosures cover double materiality, GHG emissions, renewable energy, workforce health and safety, responsible sourcing, patient access, and business conduct. Scope 1, 2 and 3 emissions were 1,097, 771 market-based, and 251,456 tonnes CO2e, respectively, and Sobi set a 37.8% absolute combined Scope 1 and 2 reduction target for 2029 from a 2023 base. The report also describes the 2024 launch of Unite4Rare and continued humanitarian support for people with haemophilia.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 31 March 2025
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
SBTi status

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services